← Back to Search

Evidence Impact on Biologics Confidence for Psoriasis

N/A
Waitlist Available
Led By Steve R Feldman, MD, PhD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with psoriasis (ICD-9: 696.1)
Age 18-80
Must not have
Currently or previously managed with a biologic medication
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day

Summary

This trial will study whether patients are more confident in the potential success of biologic medications in treating their psoriasis after being presented with clinical trial evidence, anecdotal evidence, or both.

Who is the study for?
This trial is for adults aged 18-80 with psoriasis who have never been treated with biologic medications. It aims to understand if different types of evidence can boost their confidence in using these drugs.
What is being tested?
The study tests whether presenting patients with clinical trial evidence, anecdotal evidence, both, or no evidence affects their confidence in the success of biologic medications for treating psoriasis.
What are the potential side effects?
Since this study focuses on patient perceptions rather than drug effects, it does not directly involve side effects. However, common side effects of biologics may include injection site reactions and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with psoriasis.
Select...
I am between 18 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been treated with biologic medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Oral survey responses

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Anecdotal + Research Study EvidenceActive Control1 Intervention
Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
Group II: Anecdotal EvidenceActive Control1 Intervention
Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
Group III: Research Study EvidenceActive Control1 Intervention
Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
Group IV: No EvidencePlacebo Group1 Intervention
Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,397 Previous Clinical Trials
2,459,729 Total Patients Enrolled
12 Trials studying Psoriasis
601 Patients Enrolled for Psoriasis
Steve R Feldman, MD, PhDPrincipal InvestigatorWake Forest University Health Sciences
2 Previous Clinical Trials
210 Total Patients Enrolled
1 Trials studying Psoriasis
24 Patients Enrolled for Psoriasis

Media Library

Anecdotal + Research Study Evidence Clinical Trial Eligibility Overview. Trial Name: NCT03168347 — N/A
Psoriasis Research Study Groups: Anecdotal + Research Study Evidence, Anecdotal Evidence, Research Study Evidence, No Evidence
Psoriasis Clinical Trial 2023: Anecdotal + Research Study Evidence Highlights & Side Effects. Trial Name: NCT03168347 — N/A
Anecdotal + Research Study Evidence 2023 Treatment Timeline for Medical Study. Trial Name: NCT03168347 — N/A
~47 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top